Evidence map›Paper›PMID 40009690›Full record

ArticleScience advances2025

Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant.

L Carissa Aurelia, Ruth A Purcell, Robert M Theisen, Andrew Kelly, Robyn Esterbauer, Pradhipa Ramanathan, Wen Shi Lee, Bruce D Wines, P Mark Hogarth, Jennifer A Juno and 12 more

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

L Carissa AureliaDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0009-0001-5683-8852
Ruth A PurcellDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0001-6378-5114
Robert M TheisenDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States.ORCID 0000-0002-2097-8650
Andrew KellyDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0003-2719-6544
Robyn EsterbauerDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-7091-0048
Pradhipa RamanathanDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-7390-8840
Wen Shi LeeDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0001-7285-4054
Bruce D WinesImmune Therapies Group, Burnet Institute, Melbourne, VIC, Australia.ORCID 0000-0002-4108-375X
P Mark HogarthImmune Therapies Group, Burnet Institute, Melbourne, VIC, Australia.
Jennifer A JunoDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-9072-1017
Lilith F AllenDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-4197-2573
Katherine A BondDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-4473-9232
Deborah A WilliamsonDepartment of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0001-7363-6665
Janine M TrevillyanDepartment of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-8660-5558
Jason A TrubianoDepartment of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
Thi Ho NguyenDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-9294-7693
Katherine KedzierskaDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0001-6141-335X
Adam K WheatleyDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-5593-9387
Stephen J KentDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-8539-4891
Kelly B ArnoldDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States.ORCID 0000-0003-4756-7461
Kevin John SelvaDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-0780-9422
Amy W ChungDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0003-0020-9704

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Repeated mRNA COVID-19 vaccination increases spike-specific immunoglobulin G4 (IgG4) titers. Here, we characterized the influence of increased IgG4 titers on a range of Fc-mediated responses. Elevated spike-specific IgG4 reduced binding to FcγRIIIa and decreased antibody-dependent cellular cytotoxicity. However, in individuals with lower total spike-specific IgG, IgG4 acted in synergy with other IgG subclasses to improve FcγRI and FcγRIIa binding and consequently antibody-dependent cellular phagocytosis. Furthermore, this trend was more pronounced with more recent SARS-CoV-2 variants where vaccination induced comparably lower total spike-specific titers. These observations were further confirmed by in silico modeling where antibody subclass concentrations and FcγR polymorphisms were modulated. Collectively, we illustrate that the impact of elevated IgG4 titers upon Fc functions is dependent on multiple interconnected antibody and antigen factors, which should be taken into consideration when dissecting the mechanisms driving an effective Fc-mediated response following vaccination.

Indexed as

Antibodies, ViralCOVID-19Immunoglobulin Fc FragmentsImmunoglobulin GReceptors, FcReceptors, IgGSARS-CoV-2Antibody-Dependent Cell CytotoxicityCOVID-19 VaccinesFemaleHumansPhagocytosisPolymorphism, GeneticSpike Glycoprotein, CoronavirusAntibodies, ViralCOVID-19 VaccinesFc gamma receptor IIAFCGR3A protein, humanImmunoglobulin Fc FragmentsImmunoglobulin GReceptors, FcReceptors, IgGSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID40009690
PMCPMC11864192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.